Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riociguat in adults with cystic fibrosis homozygous for F508del
NL-OMON42435Phase 2Active, not recruiting
- Sponsor
- Bayer
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of riociguat in cystic fibrosis (CF) (4 cohorts), sponsored by Bayer. Primary endpoints: Safety and tolerability and Change from baseline in sweat chloride. Started Mar 2016; status: active, not recruiting.
02
Drugs
riociguat
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON42435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42435.